Диссертация (1174220), страница 43
Текст из файла (страница 43)
- Р. 841–844.129. Cournu-Rebeix I., Génin E., Leray E. HLA-DRB1*15 allele influences the later course ofrelapsing remitting multiple sclerosis. // Genes Immun – 2008. – 9. - Р. 570-574.130. Cox E.R., Kozma C.M., Reeder C.E. Multivariate analysis of health status scores: chronic airwaydisorders and the MOS SF-36. // Pharmacoeconomics.
– 1994. - 6(1). - Р. 49-56.131. Cristiano E., Patrucco L., Miguez J. et al. Increasing incidence of multiple sclerosis amongwomen in Buenos Aires: a 22 year health maintenance organization based study. // Neurol Sci. –2016. - 37(10). - Р. 1621-1626.132. D'Amico E., Ziemssen T., Cottone S. Induction therapy for the management of early relapsingforms of multiple sclerosis. A critical opinion. // Expert Opin Pharmacother. – 2017. - 18(15). Р. 1553-1556.133.
DeLuca G.C., Ramagopalan S.V., Herrera B.M. et al. An extremes of outcome strategy providesevidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. //Proc. Natl. Acad. Sci. U. S. A. – 2007. – 104. – Р. 20896–20901.134. Dendrou C.A., Fugger L. Immunomodulation in multiple sclerosis: promises and pitfalls. // CurrOpin Immunol. – 2017. – 49. - Р. 37-43.135. Derfuss T., Kappos L. PML risk and natalizumab: the elephant in the room. // Lancet Neurol. –2017. - 16(11).
- Р. 864-865.136. Doshi A., Chataway J. Multiple sclerosis, a treatable disease. // Clin Med. – 2017. - 17(6). - Р.530-536.137. Drummond M.F., Sculpher M.J., Claxton K. et al. Methods for the economic evaluation of healthcare programmes. // 4th ed. Oxford: Oxford University Press. - 2015.138. Dyment D.A., Yee I.M., Ebers G.C. Multiple sclerosis in stepsiblings: recurrence risk andascertainment. // J Neurol Neurosurg Psychiatry. – 2006.
-77. - Р. 258-259.139. Ernstsson O., Gyllensten H., Alexanderson K. et al. Cost of illness of multiple sclerosis – Asystematic review. // PLoS ONE. – 2016. – 11. - e0159129.181140. EuropeanMedicalAgency.QuestionsandanswersonthereviewofGilenya.http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/04/WC500125689.pdf .141.
Fasczewski K.S., Rothberger S.M., Gill D.L. Why do they do it? Assessing self-report physicalactivity behavior and quality of life in individuals with multiple sclerosis. // J Health Psychol. –2017. – 1. - 1359105317739965.142. Favorova O.O., Favorov A.V., Boyko A.N. et al. Three allele combinations associated withmultiple sclerosis. // BMC Med. Genet.
– 2006. – 7. - Р. 63-70.143. Favorova O.O., Andreewski T.V., Boyko A.N. et al. The chemokine receptors CCR5 deletionmutation is associated with MS in HLA-DR4-positive Russians. // Neurology. – 2002. – 59. - Р.1652-1655.144. Fernández O., Baumstarck-Barrau K., Simeoni M.C. et al. MusiQoL study group. Patientcharacteristics and determinants of quality of life in an international population with multiplesclerosis: assessment using the MusiQoL and SF-36 questionnaires. // Mult Scler. - 2011а. 17(10).
- Р. 1238-1249.145. Fernández O., Fernández V., Baumstarck-Barrau K. et al. Validation of the spanish version ofthe Multiple Sclerosis International Quality of Life (Musiqol) questionnaire. // BMC Neurol. 2011b. – 11. - Р. 127.146. Fiest K.M., Greenfield J., Metz L.M. et al. Discriminative ability of quality of life measures inmultiple sclerosis. // Health Qual Life Outcomes. – 2017. - 15(1). - Р. 246.147. Filippi M., Rocca M.A., Ciccarelli O.
et al. MRI criteria for the diagnosis of multiple sclerosis:MAGNIMS consensus guidelines. // Lancet Neurol. – 2016. - 15(3). - Р. 292–303.148. Flachenecker P., Vogel U., Simeoni M.C. et al. MusiQol: international questionnaireinvestigating quality of life in multiple sclerosis: validation results for the German subpopulationin an international comparison. // Der Nervenarzt.
– 2011. - 82(10). - Р. 1281–1289.149. Foley J.F., Nair K.V., Vollmer T. et al Long-term natalizumab treatment is associated withsustained improvements in quality of life in patients with multiple sclerosis. // Patient PreferAdherence. – 2017. – 11. - Р. 1035-1048.150. Ford C.C. Long-term experience with current disease-modifying drugs in multiple sclerosis. // JNeurol. – 2006. - 253 (Suppl 6). - vi37-vi44.151.
Fox R., Rudick R. Risk stratificationand patient counseling for natalizumab in multiple sclerosis.// Neurology. – 2012. – 78. - Р. 436–437.152. Fox R.J., Miller D.H., Phillips J.T. et al. Placebo-controlled phase 3 study of oral BG-12 orglatiramer in multiple sclerosis. // N Engl J Med. – 2012. – 367. - Р. 1087-1097.182153. Freeman J.A., Hobart J.C., Thompson A.J. Does adding MS-specific items to a generic measure(the SF-36) improve measurement? // Neurology. – 2001.
- 57(1). - Р. 68-74.154. Freeman J.A., Langdon D.W., Hobart J.C. et al. Health-related quality of life in people withmultiple sclerosis undergoing inpatients rehabilitation. // J Neuro Rehab – 1996. – 10. - Р. 185194.155. Füvesi J., Bencsik K., Benedek K. et al. Cross-cultural adaptation and validation of the ‘MultipleSclerosis Quality of Life Instrument‘ in Hungarian. // Multiple Sclerosis. – 2008.
-14(3). - Р.391–398.156. Giovannoni G., Butzkueven H., Dhib-Jalbut S. et al. Brain health: Time matters in multiplesclerosis. // Mult Scler Relat Disord – 2016. - 9(Suppl. 1). – Р. 5–48.157. Gold R., Kappos L., Arnold D.L. et al. Placebo-controlled phase 3 study of oral BG-12 forrelapsing multiple sclerosis. // N Engl J Med. – 2012.
– 367. - Р. 1098-1107.158. Gold R., Rieckmann P., Chang P. et al. The long-term safety and tolerability of high-doseinterferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study.// Eur J Neurol. – 2005. - 12(8). - Р. 649-656.159. Gold S.M., Schulz H., Monch A. et al. Cognitive impairment in multiple sclerosis does not affectreliability and validity of self-report health measures.
// Mult Scler. – 2003. – 11. - Р. 404–410.160. Gold S.M., Schulz H., Mönch A., Schulz K.H., Heesen C. Cognitive impairment in multiplesclerosis does not affect reliability and validity of self-report health measures. // Mult Scler. –2003. - 9(4). - Р. 404-410.161. Goodin D.S., Frohman E.M., Hurwitz B. et al. Neutralizing antibodies to interferon beta:assessment of their clinical and radiographic impact: an evidence report: report of theTherapeutics and Technology Assessment Subcommittee of the American Academy ofNeurology.
// Neurology. – 2007. – 68. - Р. 977-984.162. Gregory S.G., Schmidt S., Seth P. et al. Multiple Sclerosis Genetics Group. Interleukin 7 receptoralpha chain (IL7R) shows allelic and functional association with multiple sclerosis. // Nat. Genet.– 2007. – 39. - Р.
1083-1091.163. Grytten N., Aarseth J.H., Lunde H.M., Myhr K.M. A 60-year follow-up of the incidence andprevalence of multiple sclerosis in Hordaland County, Western Norway. // J Neurol NeurosurgPsychiatry. – 2016. - 87(1). - Р. 100-105.164. Guarnaccia J.B., Aslan M., O‘Connor T.Z. et al. Quality of life for veterans with multiplesclerosis on disease-modifying agents: relationship to disability. J Rehab Res Devel – 2006.
43(1). – Р. 35–44.165. Guerini F.R., Ferrante P., Losciale L. et al. Myelin basic protein gene is associated with MS inDR4- and DR5-positive Italians and Russians. // Neurology. – 2003. – 61. - Р. 520-526.183166. Gusev E.., Boyko A, Bikova O. et al. The natural history of early onset multiple sclerosis:comparison of data from Moscow and Vancouver.
// Clin Neurol Neurosurg – 2002. – 104. – Р.203-207.167. Gusev E., Boyko A., Lauer K. et al. Environmental risk factors in MS: a case-control study inMoscow. // Acta Neurol Scand – 1996. – 94. - Р. 386-394.168. Gyang T.V., Hamel J., Goodman A.D. et al. Fingolimod-associated PML in a patient with priorimmunosuppression. // Neurology – 2016. - 86(19). - Р.
1843-1845.169. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J. et al. Risk alleles for multiplesclerosis identified by a genomewide study. // N Engl J Med – 2007. – 357. - Р. 851–862.170. Handunnetthi L., Handel A.E., Ramagopalan S.V. Contribution of genetic, epigenetic andtranscriptomic differences to twin discordance in multiple sclerosis. // Expert Rev Neurother.
–2010. – 10. - Р. 1379-1381.171. Hauser S.L., Bar-Or A., Comi G. et al. Ocrelizumab versus Interferon Beta-1a in RelapsingMultiple Sclerosis. // N Engl J Med. – 2017. - 376(3). - Р. 221-234.172. Hedström A.K., Katsoulis M., Hössjer O. et al. The interaction between smoking and HLA genesin multiple sclerosis: replication and refinement. // Eur J Epidemiol.
– 2017. - 32(10). - Р. 909919.173. Heiskanen S., Meriläinen P., Pietilä A.M. Health-related quality of life-testing the reliability ofthe MSQOL-54 instrument among MS patients. // Scand J Caring Sci. – 2007. - 21(2). - Р. 199206.174. Henriksson F. & Jonsson B. The economic cost of multiple sclerosis in Sweden in 1994. //Pharmacoeconomics – 1998. – 13. - Р. 597–606.175.
Henriksson F., Fredricson S., Masterman T., Jonsson B. Costs, quality of life and diseaseseverity in multiple sclerosis: a cross-sectional study in Sweden. // Eur J Neurol – 2001. - 8. - Р.27 –35.176. Herbstritt S., Langer-Gould A., Rockhoff M. et al. Glatiramer acetate during early pregnancy: Aprospective cohort study. // Mult Scler.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
